TruScreen Announces Initial Zimbabwe Order

14 September 2018 NZX Announcement TruScreen HIV African Initiative Update Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) ("Truscreen") advises that, following on from its deliberations with senior African health officials as announced on 27 August 2018 it has now received an initial order to the value of approximately NZ$450,000 from the National Aids Council of Zimbabwe to supply cervical cancer screening systems ("systems"). It is expected that the order will be completed within 30 days. The Truscreen cervical cancer screening systems will be used in Stage 1 of a pilot program to provide cervical cancer screening to HIV affected women in Zimbabwe. Deliberations to supply further systems to the National Aids Council of Zimbabwe are continuing. There are over 720,000 HIV affected women in Zimbabwe, and 13 million HIV affected women in Africa, and these women are 6 times more likely to suffer from cervical cancer than other women. TruScreen chair, Robert Hunter, said "This pilot program is the first step in our strategy to bring advanced cervical cancer screening methods to the women of Africa, and in particular to the 13 million HIV affected women in Africa. TruScreen is the ideal solution to provide cervical cancer screening to these women, and to other women in other region who do not have access to traditional laboratory dependant screening methods" ENDS For more information visit www.truscreen.com or contact: Martin Dillon TruScreen Chief Executive Officer Email: martindillon@truscreen.com Media Liaison Jackie Ellis Email: jackie@ellisandco.co.nz Phone: +64 27 246 2505 About TruScreen: TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection. End CA:00323900 For:TRU Type:GENERAL Time:2018-09-14 12:01:07